Managing Director Dr Ross Macdonald spoke to Matt Birney on the Bulls N’ Bears Report about the FDA clearing Cynata’sInvestigational New Drug (IND) application for a Phase 2 acute graft versus host disease (aGvHD) trial adding yet another indication to Cynata's broad and robust clinical pipeline.
In exciting news, the US FDA cleared Cynata’s Investigational New Drug (IND) application for a Phase 2 clinical trial of CYP-001 in patients with acute graft versus host disease (aGvHD). The planned Phase 2 clinical trial will seek to recruit approximately 60 patients with high risk aGvHD, at clinical centres in several countries, including the US and Australia. FDA clearance is a major achievement and valuation milestone for the Company.
The stock was up 10 per cent following the announcement, read the full details on The Australian:
Joining Cynata as Chief Medical Officer in October 2021, Dr Jolanta Airey sat down with ValiantCEO for International Women’s Day to discuss her motivations, her career journey to date and her advice for women in STEM. If you’d like to be inspired, the full interview is here:
In late February, Cynata received a notice of Decision to Grant from the State Intellectual Property Office of the People’s Republic of China (SIPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell (MSC) technology (scroll to after the table):